Abstract
Aim: Determine whether using CYP2C19 genotype to optimize antiplatelet therapy selection is cost effective over the initial 30 days and 1-year following percutaneous coronary intervention. Materials & methods: A cost-effectiveness analysis compared 30-day and 1-year outcomes and cost across three treatment strategies (universal clopidogrel, universal prasugrel, genotype-guided) in a hypothetical cohort. Results: Base-case scenario results at 30 days indicated that the incremental cost per major cardiovascular or bleeding event avoided for genotype-guided treatment was US8525 and US42,198 compared with universal clopidogrel and prasugrel, respectively. Probabilistic sensitivity analysis demonstrated that genotype-guided treatment was cost effective over 30 days and 1 year in 62 and 70% of simulations, respectively. Conclusion: Implementing a CYP2C19 genotype-guided approach to antiplatelet therapy could have a positive economic impact by preventing readmissions following percutaneous coronary intervention.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1155-1166 |
| Number of pages | 12 |
| Journal | Pharmacogenomics |
| Volume | 18 |
| Issue number | 12 |
| DOIs | |
| State | Published - Aug 2017 |
Bibliographical note
Publisher Copyright:© 2017 2017 Future Medicine Ltd.
Keywords
- CYP2C19
- clopidogrel
- cost-effectiveness
- genotype
- pharmacogenomics
- prasugrel
- readmission
